Fragmin injection: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 3: Line 3:
|fdaLIADAdult=123
|fdaLIADAdult=123
|fdaLIADPed=12312312312312
|fdaLIADPed=12312312312312
|clinicalTrials=123123
|hasUsageInfo=In Progress
|hasUsageInfo=In Progress
}}
}}

Latest revision as of 12:34, 20 March 2014

Fragmin injection®
Black Box Warning
Adult Indications and Dosage
Pediatric Indications and Dosage
Contraindications
Warnings
Adverse Reactions
Drug Interactions
Use in Specific Populations
Routes and Preparations
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient information
Precautions with Alcohol
Look-Alike Drug Names
Drug Shortage Status
Price

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]{{{authorTag}}}

For information about {{{genericName}}}, click here.

Disclaimer

Overview

Fragmin injection is a {{{drugClass}}} drug that is FDA approved for the treatment of {{{indication}}}. Adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)
Off-Label Use and Dosage (Adult)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)
Off-Label Use and Dosage (Pediatric)

Contraindications

Warnings

Adverse Reactions

Clinical Trials Experience
Postmarketing Experience

Drug Interactions

Use in Specific Populations

Pregnancy
Labor and Delivery
Nursing Mothers
Pediatric Use
Geriatric Use
Gender
Race
Renal Impairment
Hepatic Impairment
Females of Reproductive Potential and Males
Immunocompromised Patients

Routes and Preparations

Routes
Preparations

IV Compatibility

Overdosage

Pharmacology

Mechanism of Action
Structure
Pharmacodynamics
Pharmacokinetics
Nonclinical Toxicology

Clinical Studies

How Supplied

Images

Drug Images
Package and Label Display Panel

Patient Information

Patient Information from FDA

Patient Information from NLM

Look-Alike Drug Names

Price

Drug Shortage


Adult Indications and Dosage

Below is the code to be placed on the Adult Indications and Dosage Microchapeter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}


===FDA-Labeled Indications and Dosage (Adult)===

123

===Off-Label Use and Dosage (Adult)===

{{{offLabelAdult}}}

{{DrugReflist}}

Pediatric Indications and Dosage

Below is the code to be placed on the Adult Indications and Dosage Microchapeter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}


===FDA-Labeled Indications and Dosage (Pediatric)===

12312312312312

===Off-Label Use and Dosage (Pediatric)===

{{{offLabelPed}}}

{{DrugReflist}}



Use in Specific Populations

Below is the code to be placed on the Drug Interaction Microchapter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}


===Pregnancy===

: '''[[Pregnancy category#United States|Pregnancy Category (FDA)]]'''

There is no FDA guidance on usage of {{BASEPAGENAME}} in women who are pregnant.

:'''[[Pregnancy category#Australia|Pregnancy Category (AUS)]]'''

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{BASEPAGENAME}} in women who are pregnant.

===Labor and Delivery===

There is no FDA guidance on use of {{BASEPAGENAME}} during labor and delivery.

===Nursing Mothers===

There is no FDA guidance on the use of {{BASEPAGENAME}} in women who are nursing.

===Pediatric Use===

There is no FDA guidance on the use of {{BASEPAGENAME}} in pediatric settings.

===Geriatic Use===

There is no FDA guidance on the use of {{BASEPAGENAME}} in geriatric settings.

===Gender===

There is no FDA guidance on the use of {{BASEPAGENAME}} with respect to specific gender populations.

===Race===

There is no FDA guidance on the use of {BASEPAGENAME}} with respect to specific racial populations.

===Renal Impairment===

There is no FDA guidance on the use of {{BASEPAGENAME}} in patients with renal impairment.

===Hepatic Impairment===

There is no FDA guidance on the use of {{BASEPAGENAME}} in patients with hepatic impairment.

===Females of Reproductive Potential and Males===

There is no FDA guidance on the use of {{BASEPAGENAME}} in women of reproductive potentials and males.

===Immunocompromised Patients===

There is no FDA guidance one the use of {{BASEPAGENAME}} in patients who are immunocompromised.

{{DrugReflist}}


Overdose

Below is the code to be placed on the Overdose Microchapter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}

'''Please contact the National Poison Help hotline (1-800-222-1222) immediately if there is suspicion of drug poisoning or overdose.'''

===Overdose===

{{{overdose}}}

{{DrugReflist}}

Pharmacology

Below is the code to be placed on the Pharmacology Microchapter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}

===Mechanism of Action===

{{{mechAction}}}

===Structure===

{{{structure}}}

===Pharmacodynamics===

{{{PD}}}

===Pharmacokinetics===

{{{PK}}}

===Nonclinical Toxicology===

{{{nonClinToxic}}}

{{DrugReflist}}